Cellergy test food preserative as skin disease treatment

- Glycerol molaurate, a compound currently used as a food preservative, has entered into Phase III clinical trials for the treatment of non-bullous congenital ichthyosiform erythroderma. Cellegy Pharmaceuticals, which has been granted orphan drug status on the chemical for the treatment of congenital primary ichthyosis, found in early studies that the drug candidate (trade named Glylorin) showed both antibacterial and anti-inflammatory properties. In Phase II, Glylorin reduced disease symptoms (scaling) by around 50%-70%, vs 25%-35% for control.